502 related articles for article (PubMed ID: 28895030)
1. Type 2 diabetes and cardiovascular prevention: the dogmas disputed.
Giugliano D; Maiorino MI; Bellastella G; Esposito K
Endocrine; 2018 May; 60(2):224-228. PubMed ID: 28895030
[TBL] [Abstract][Full Text] [Related]
2. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
3. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
Scheen AJ
Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.
Bailey CJ; Marx N
Diabetes Obes Metab; 2019 Jan; 21(1):3-14. PubMed ID: 30091169
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Protection with Anti-hyperglycemic Agents.
Deedwania P; Acharya T
Am J Cardiovasc Drugs; 2019 Jun; 19(3):249-257. PubMed ID: 30767126
[TBL] [Abstract][Full Text] [Related]
8. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
Kaul S
Diabetes Care; 2017 Jul; 40(7):821-831. PubMed ID: 28637887
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety outcomes of new antidiabetic therapies.
LeBras MH; Barry AR; Koshman SL
Am J Health Syst Pharm; 2017 Jul; 74(13):970-976. PubMed ID: 28483748
[TBL] [Abstract][Full Text] [Related]
10. Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs.
Chawla H; Tandon N
Am J Cardiovasc Drugs; 2017 Jun; 17(3):203-215. PubMed ID: 28197977
[TBL] [Abstract][Full Text] [Related]
11. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
Secrest MH; Udell JA; Filion KB
Trends Cardiovasc Med; 2017 Apr; 27(3):194-202. PubMed ID: 28291655
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Outcomes of New Medications for Type 2 Diabetes.
Trujillo JM; Wettergreen SA; Nuffer WA; Ellis SL; McDermott MT
Diabetes Technol Ther; 2016 Dec; 18(12):749-758. PubMed ID: 27835045
[TBL] [Abstract][Full Text] [Related]
13. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
Eleftheriadou I; Grigoropoulou P; Liberopoulos E; Liatis S; Kokkinos A; Tentolouris N
Curr Med Chem; 2018; 25(13):1549-1566. PubMed ID: 28554326
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
15. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
Bonadonna RC; Borghi C; Consoli A; Volpe M
Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
[TBL] [Abstract][Full Text] [Related]
16. SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):429-442. PubMed ID: 28121469
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions.
Herbst R; Bolton W; Shariff A; Green JB
Curr Diab Rep; 2017 Sep; 17(9):67. PubMed ID: 28726152
[TBL] [Abstract][Full Text] [Related]
18. Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
Cheng JWM; Badreldin HA; Patel DK; Bhatt SH
Curr Med Res Opin; 2017 Jun; 33(6):985-992. PubMed ID: 28097882
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists.
Scheen AJ
Diabetes Res Clin Pract; 2017 May; 127():224-237. PubMed ID: 28402902
[TBL] [Abstract][Full Text] [Related]
20. Managing Diabetes and Preventing Heart Disease: Have We Found a Safe and Effective Agent?
Cheng JWM; Colucci VJ; Kalus JS; Spinler SA
Ann Pharmacother; 2019 May; 53(5):510-522. PubMed ID: 30516068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
